tumor necrosis factor receptor 2 | Tumour necrosis factor (TNF) receptor family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

tumor necrosis factor receptor 2

  Target has curated data in GtoImmuPdb

Target id: 1871

Nomenclature: tumor necrosis factor receptor 2

Abbreviated Name: TNFR2

Systematic Nomenclature: TNFRSF1B

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 461 01p36.22 TNFRSF1B TNF receptor superfamily member 1B
Mouse 1 474 Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b
Rat 1 474 Tnfrsf1b TNF receptor superfamily member 1B
Previous and Unofficial Names
CD120b | TNF-R2 | p75 TNFR | TNFalpha-R2 | TNF-R75 | TNFRII | tumor necrosis factor receptor superfamily, member 1B | tumor necrosis factor receptor superfamily
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Natural/Endogenous Ligands
lymphotoxin-α {Sp: Human}
tumour necrosis factor membrane form {Sp: Human}
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF5
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Value Parameter Reference
lymphotoxin-α {Sp: Human} Hs - - -
tumour necrosis factor membrane form {Sp: Human} Hs - - -
Immunopharmacology Comments
TNFR2 is a receptor for lymphotoxin-α, and the membrane form of tumour necrosis factor (TNF). It plays a variety of important roles in immune system development and regulation [4-5], mediating immune suppression and tissue regeneration. It achieves immune suppression by influencing activation and proliferation of TNFR2-expressing Treg cells [2]. TNFR2 on Treg cells in the tumour microenvironment and on tumour cells is considered to be a therapeutically tractable target for novel immuno-oncology agents [7]. TNFR2 antagonistic antibodies [3] have the potential to reduce Treg and cancer cell activation and/or proliferation [1,6], and concomittantly promote proliferation of Teff cells, further contributing to immune system-mediated destruction of tumour cells.
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 6 GO processes
GO:0002724 regulation of T cell cytokine production ISS
GO:0043312 neutrophil degranulation TAS
GO:0150077 regulation of neuroinflammatory response ISS
GO:0150079 negative regulation of neuroinflammatory response ISS
click arrow to show/hide IEA associations
GO:0006954 inflammatory response IEA
GO:0050728 negative regulation of inflammatory response IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 5 GO processes
GO:0002724 regulation of T cell cytokine production ISS
GO:0002739 regulation of cytokine secretion involved in immune response ISS
GO:0005031 tumor necrosis factor-activated receptor activity TAS
GO:0019221 cytokine-mediated signaling pathway TAS
GO:0033209 tumor necrosis factor-mediated signaling pathway TAS
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 2 GO processes
GO:0042129 regulation of T cell proliferation ISS
GO:0043312 neutrophil degranulation TAS
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes
GO:0002724 regulation of T cell cytokine production ISS
Immuno Process:  Immune regulation
GO Annotations:  Associated to 6 GO processes, IEA only
GO:0002724 regulation of T cell cytokine production ISS
GO:0002739 regulation of cytokine secretion involved in immune response ISS
GO:0042129 regulation of T cell proliferation ISS
GO:0150077 regulation of neuroinflammatory response ISS
GO:0150079 negative regulation of neuroinflammatory response ISS
click arrow to show/hide IEA associations
GO:0050728 negative regulation of inflammatory response IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 2 GO processes
GO:0002724 regulation of T cell cytokine production ISS
GO:0042129 regulation of T cell proliferation ISS

References

Show »

1. Chen X, Oppenheim JJ. (2017) Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal, 10 (462). [PMID:28096506]

2. Chen X, Wu X, Zhou Q, Howard OM, Netea MG, Oppenheim JJ. (2013) TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J. Immunol., 190 (3): 1076-84. [PMID:23277487]

3. Fischer R, Marsal J, Guttà C, Eisler SA, Peters N, Bethea JR, Pfizenmaier K, Kontermann RE. (2017) Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep, 7 (1): 6607. [PMID:28747780]

4. Gubernatorova EO, Tumanov AV. (2016) Tumor Necrosis Factor and Lymphotoxin in Regulation of Intestinal Inflammation. Biochemistry Mosc., 81 (11): 1309-1325. [PMID:27914457]

5. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG. (1999) Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med., 189 (2): 403-12. [PMID:9892622]

6. Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D et al.. (2017) Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal, 10 (462). [PMID:28096513]

7. Vanamee ÉS, Faustman DL. (2017) TNFR2: A Novel Target for Cancer Immunotherapy. Trends Mol Med, 23 (11): 1037-1046. [PMID:29032004]

Contributors

Show »

How to cite this page

Select citation format: